April 2022 marks an eventful year since Dr. Wojciech Swat started as Director of Cancer Genomics Service at GenPath® Diagnostics, a division of BioReference Laboratories.
Dr. Swat had previously trained at several prestigious institutions, including The Basel Institute for Immunology and Harvard Medical School, and immediately prior to joining the BioReference team, Dr. Swat spent over two decades investigating the molecular pathways of cancer at the Siteman Cancer Center and Barnes-Jewish Hospital in St. Louis, Missouri. As a tenured faculty member of the Washington University School of Medicine’s Department of Pathology and Immunology, Dr. Swat contributed over 100 publications and numerous lectureships to help develop the very tools currently entering the commercial space of leading cancer diagnostics outfits.
From the time he started at GenPath®, Dr. Swat’s focus has been to provide clients and patients with an unmatched quality of clinical service. This goal has been achieved by consolidating GenPath®’s diversified molecular platforms, entering the MRD testing space with a focus on delivering industry-leading TATs (turnaround times), developing strong wet lab/dry lab teams, and building strategic collaborations with other industry leaders.
GenPath® leads the Sequoia group multicenter study on complex NGS biomarkers in Cancer Genomics, including TMB and tumor-only MSI, and the new biomarker in ovarian and prostatic cancers called HRD. Dr. Swat was among the presenters at the New York Bio2022 patient outreach forum to discuss the practical implications of these novel biomarkers entering cancer clinics. He also leads the weekly discussion of challenging cancer cases at the Molecular Tumor Board of Tufts Medical Center.
When not working on developing new strategic approaches to improve GenPath®’s cancer diagnostic services, Dr. Swat likes to spend his time boating off the coast of New Jersey and New York – entertaining his wife and three teenage daughters and practicing water sports on local rivers and Lake Hopatcong.